



## IMAGES IN PAEDIATRICS

### A suspicious wink

#### Un guiño poco inocente



Inés Marín-Cruz<sup>a,\*</sup>, Erik J. Bordón-Sardiña<sup>b</sup>, Luis M. Prieto-Tato<sup>a</sup>

<sup>a</sup> Unidad de Enfermedades Infecciosas, Servicio de Pediatría, Hospital Universitario 12 de Octubre, Madrid, Spain

<sup>b</sup> Servicio de Pediatría, Complejo Hospitalario Universitario Materno Infantil de Las Palmas, Las Palmas Gran Canaria, Spain

Available online 26 August 2023

A neonate presented at 7 days post birth with eyelid swelling and epiphora in the left eye. The physical examination revealed conjunctival hyperaemia and a yellowish exudate (Fig. 1). She had received ophthalmic prophylaxis with chlortetracycline eye drops at birth.

A sample of the exudate was obtained for culture and a 7-day course of erythromycin prescribed, and the symptoms resolved. Penicillin-sensitive *Neisseria meningitidis* was isolated from the culture. Given the potential for progression to invasive meningococcal disease (IMD), the patient received treatment with oral amoxicillin for 10 days and the parents a single dose of ciprofloxacin for pharmacological prophylaxis. The patient was vaccinated against meningococcal disease with the ACWY vaccine (first dose at 6 weeks post birth) and the meningococcal B vaccine (first dose at 2.5 months post birth). She remained asymptomatic in the 4 months of follow-up.

*Neisseria meningitidis* is rarely the causative agent involved in ophthalmia neonatorum, but it carries the risk of severe disease, as the infection may progress to IMD (10%–29% of cases of primary meningococcal conjunctivitis).<sup>1</sup> Systemic antibiotic therapy is recommended, as the risk of developing IMD in patients with primary meningococcal conjunctivitis treated solely with



**Figure 1** Female neonate with swelling of the left eyelid at 7 days post birth.

topical antibiotics is 19 times greater compared to those who receive systemic antibiotics.<sup>2</sup> Given the probability of IMD in close contacts, chemoprophylaxis and vaccination (in the case of infection by group A, C, W or Y meningococcus) are also recommended.<sup>3</sup>

\* Corresponding author.

E-mail address: [marincruz.i@gmail.com](mailto:marincruz.i@gmail.com) (I. Marín-Cruz).

## References

1. Parikh SR, Campbell H, Mandal S, Ramsay ME, Ladhani SN. Primary meningococcal conjunctivitis: summary of evidence for the clinical and public health management of cases and close contacts. *J Infection*. 2019;79:490–4.
2. Barquet N, Gasser I, Domingo P, Moraga FA, Macaya A, Elcuaz R. Primary meningococcal conjunctivitis: report of 21 patients and review. *Rev Infect Dis*. 1990;12:838–47.
3. Communicable Diseases Network Australia [Accessed 1 November 2022]. Available from: Australia CDN invasive meningococcal disease CDNA national guidelines for public health units. 12 edn Australia: Department of Health; 2017 <https://www.health.gov.au/sites/default/files/documents/2020/02/invasive-meningococcal-disease-cdna-national-guidelines-for-public-health-units.pdf>